大理大学学报 ›› 2026, Vol. 11 ›› Issue (2): 37-41.DOI: 10. 3969 / j. issn. 2096-2266. 2026. 02. 006

• 临床医学 • 上一篇    下一篇

食管癌根治术联合放化疗对中晚期食管癌患者临床疗效及#br# 免疫功能影响

魏 壮1,胡阳阳2   

  1. (1. 沭阳县中医院胸心外科,江苏宿迁 223600; 2. 沭阳县中医院肿瘤科,江苏宿迁 223600)
  • 收稿日期:2025-10-23 修回日期:2025-11-25 出版日期:2026-02-15 发布日期:2026-03-18
  • 作者简介:魏壮,主治医师,主要从事胸心外科研究。
  • 基金资助:
    江苏省卫生健康委员会科研基金资助项目(Z2023083)

Effects of Radical Esophagectomy Combined with Chemoradiotherapy on Clinical Efficacy and Immune#br# Function in Patients with Advanced Esophageal Cancer

Wei Zhuang1, Hu Yangyang2   

  1. (1. Department of Thoracic and Cardiac Surgery, Shuyang County Traditional Chinese Medicine Hospital, Suqian, Jiangsu 223600,
    China; 2. Department of Oncology, Shuyang County Traditional Chinese Medicine Hospital, Suqian, Jiangsu 223600, China)
  • Received:2025-10-23 Revised:2025-11-25 Online:2026-02-15 Published:2026-03-18

摘要: 目的:探讨食管癌根治术联合放化疗在中晚期食管癌治疗中的临床效果及其对患者免疫功能的影响。方法:选取2023
年12月至2025年1月沭阳县中医院收治的98例中晚期食管癌患者,随机将其分为对照组和干预组。对照组实施单纯食管癌
根治术,干预组在对照组基础上联合放化疗治疗。比较2组患者临床疗效、免疫功能指标和血清肿瘤标志物水平,并比较不良
反应发生情况。结果:干预组总有效率显著高于对照组(P<0.05),治疗12周后干预组CD3+水平显著升高,CD8+和CD4+水平、
CD4+/CD8+比值显著降低,血清肿瘤标志物(癌胚抗原、细胞角质蛋白19片段抗原21-1)水平显著降低,与对照组比较差异均有
统计学意义(P<0.01)。2组患者不良反应发生率差异无统计学意义(P>0.05)。结论:食管癌根治术联合放化疗可显著提高中
晚期食管癌患者的治疗有效率,改善免疫功能并降低肿瘤标志物水平,在安全性可控的前提下具有较高的临床应用价值,值得
进一步验证与推广。

关键词: 食管癌, 根治术, 放化疗, 免疫功能, 血清肿瘤标志物

Abstract: Objective: To evaluate the clinical efficacy of radical esophagectomy combined with chemoradiotherapy in patients with
advanced esophageal cancer and its impact on immune function. Methods: Ninety-eight patients with advanced esophageal cancer ad⁃
mitted to Shuyang County Traditional Chinese Medicine Hospital between December 2023 and January 2025 were randomly divided
into a control group (radical surgery alone) and an intervention group (radical surgery plus chemoradiotherapy). Clinical efficacy, im⁃
mune function indicators, serum tumor markers, and adverse reactions were compared between groups. Results: The total effective rate
in the intervention group was significantly higher than that in the control group (P<0.05). After 12 weeks of treatment, the intervention
group showed significantly increased in CD3+ levels and decreased in CD4+ and CD8+ levels,and the ratio of CD4+/CD8+, along with re⁃
duced serum levels of carcinoembryonic antigen and cyto-keratin-19 fragment antigen 21-1 (P<0.01). No significant difference in ad⁃
verse reaction rates was observed between groups (P>0.05). Conclusion: Radical esophagectomy combined with chemoradiotherapy
significantly improves treatment efficacy, enhances immune function, and reduces tumor marker levels in patients with advanced
esophageal cancer, demonstrating favorable safety and clinical application value.

Key words: esophageal cancer, radical surgery, chemoradiotherapy, immune function, serum tumor markers

中图分类号: